29 results on '"Malyszko, Jolanta"'
Search Results
2. Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant
- Author
-
Malyszko, Jolanta, Koc-Zorawska, Ewa, Kozminski, Piotr, and Malyszko, Jacek S.
- Published
- 2017
- Full Text
- View/download PDF
3. Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?
- Author
-
Liabeuf, Sophie, Pepin, Marion, Franssen, Casper, Viggiano, Davide, Carriazo, Sol, Gansevoort, Ron, Gesualdo, Loreto, Hafez, Gaye, Malyszko, Jolanta, Mayer, Christopher, Nitsch, Dorothea, Ortiz, Alberto, Pešić, Vesna, Wiecek, Andrzej, Massy, Ziad, Capasso, Giovambattista, Andrade, Alexandre, Bachmann, Maie, Bumblyte, Inga, Covic, Adrian Constantin, Delgado, Pilar, Endlich, Nicole, Engvig, Andreas, Fouque, Denis, Frische, Sebastian, Garneata, Liliana, Giannakou, Konstantinos, Goumenos, Dimitrios, Kartal, Ayşe Tuğba, Mani, Laila-Yasmin, Marti, Hans-Peter, Nielsen, Rikke, Rroji, Merita, Sakkas, Giorgos, Spasovski, Goce, Stevens, Kate, Vazelov, Evgueniy, Zacharia, Lefteris, Ferreira, Ana Carina, Hoorn, Ewout, Figurek, Andreja, Unwin, Robert, Wagner, Carsten, Wanner, Christoph, BRUCHFELD, Annette, Fridolin, Ivo, Romeo, Maria José Soler, Barbieri, Michelangela, Batinić, Bojan, Carrasco, Laura, Martino, Gianvito, Raso, Francesco Mattace, Nistor, Ionut, Paolisso, Giuseppe, Rastenytė, Daiva, Stefan, Gabriel, Tedeschi, Gioacchino, Bikbov, Boris, Endlich, Karl Hans, Godefroy, Olivier, Chillon, Jean-Marc, Kossioni, Anastassia, Kurganaite, Justina, Perico, Norberto, Remuzzi, Giuseppe, Grodzicki, Tomasz, Trepiccione, Francesco, Zoccali, Carmine, Arici, Mustafa, Blankestijn, Peter, Eckardt, Kai-Uwe, Fliser, Danilo, Jiménez, Eugenio Gutiérrez, Konig, Maximilian, Rychlik, Ivan, Deleidi, Michela, REUSZ, George, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Hôpital Ambroise Paré [AP-HP], Groningen University Medical Centre, Department of Nephrology [Groningue, Pays-Bas], University Medical Center Groningen [Groningen] (UMCG), CeRTA, Liabeuf, S., Pepin, M., Franssen, C. F. M., Viggiano, D., Carriazo, S., Gansevoort, R. T., Gesualdo, L., Hafez, G., Malyszko, J., Mayer, C., Nitsch, D., Ortiz, A., Pesic, V., Wiecek, A., and Massy, Z. A.
- Subjects
medicine.medical_specialty ,CLINICAL-OUTCOMES ,HEMODIALYSIS ,Movement disorders ,030232 urology & nephrology ,RENAL DYSFUNCTION ,URIC-ACID ,Review ,03 medical and health sciences ,0302 clinical medicine ,PARKINSONS-DISEASE ,Diabetes mellitus ,Internal medicine ,Epidemiology ,medicine ,CKD ,INDOXYL SULFATE ,AcademicSubjects/MED00340 ,Stroke ,Depression (differential diagnoses) ,RISK ,Transplantation ,Kidney ,COMPLICATIONS ,business.industry ,cardiovascular ,medicine.disease ,COGNITIVE FUNCTION ,indoxyl sulphate ,stroke ,3. Good health ,medicine.anatomical_structure ,Clinical research ,Nephrology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Kidney disease ,uraemic toxins - Abstract
Chronic kidney disease (CKD) perturbs the crosstalk with others organs, with the interaction between the kidneys and the heart having been studied most intensively. However, a growing body of data indicates that there is an association between kidney dysfunction and disorders of the central nervous system. In epidemiological studies, CKD is associated with a high prevalence of neurological complications, such as cerebrovascular disorders, movement disorders, cognitive impairment and depression. Along with traditional cardiovascular risk factors (such as diabetes, inflammation, hypertension and dyslipidaemia), non-traditional risk factors related to kidney damage (such as uraemic toxins) may predispose patients with CKD to neurological disorders. There is increasing evidence to show that uraemic toxins, for example indoxyl sulphate, have a neurotoxic effect. A better understanding of factors responsible for the elevated prevalence of neurological disorders among patients with CKD might facilitate the development of novel treatments. Here, we review (i) the potential clinical impact of CKD on cerebrovascular and neurological complications, (ii) the mechanisms underlying the uraemic toxins’ putative action (based on pre-clinical and clinical research) and (iii) the potential impact of these findings on patient care., Graphical Abstract Graphical Abstract
- Published
- 2021
4. Green Dialysis: Let Us Talk about Dialysis Fluid.
- Author
-
Zawierucha, Jacek, Marcinkowski, Wojciech, Prystacki, Tomasz, Malyszko, Jacek S., Pyrza, Michal, Zebrowski, Pawel, and Malyszko, Jolanta
- Subjects
DIALYSIS (Chemistry) ,HEMODIALYSIS facilities ,HEMODIALYSIS ,HEMODIALYSIS patients ,PLASTIC containers ,BLOOD flow - Abstract
Background: Hemodialysis is one of the most resources consuming medical intervention. Due to its concept, the proper amount of dialysis fluid passed through dialyzer is crucial to obtain the expected outcomes. The most frequent source of dialysis fluid is production from liquid concentrate (delivered in containers or plastic bags) in dialysis machine. Alternatively, concentrates for dialysis may be produced in dialysis center by dilution in mixing devices dry or semidry premixed compounds connected with system of central dialysis fluid delivery system. Dialysate consumption depends on various factors like type of hemodialysis machine, session duration, prescribed flow, etc. Summary: Modern hemodialysis machines are equipped with the modules which automatically reduce flow rate of dialysis fluid to the patient blood flow and minimize dialysate consumption during preparation and after reinfusion. Smart using of available options offered by manufacturers allows to save additional portion of acid concentrate and water. The weight of concentrates to be delivered to the dialysis center is the major factor influencing the cost (financial and environmental) of transportation from the manufacturer to the final consumer. The crisis on the energy carriers market and extremely high fuel prices made the transportation cost one of the significant costs of the treatment, which must be bear by supplier and finally influence on the price of goods. Key Messages: The careful choice of the concentrate delivery system can improve cost-effectiveness of dialysis. Such solutions implemented in dialysis unit helps make significant savings and decrease the impact on natural environment by carbon footprint reduction. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Main Barriers to the Introduction of a Home Haemodialysis Programme in Poland: A Review of the Challenges for Implementation and Criteria for a Successful Programme.
- Author
-
Kendzia, Dana, Lima, Federica, Zawierucha, Jacek, Busink, Ellen, Apel, Christian, Malyszko, Jacek Stanislaw, Zebrowski, Pawel, and Malyszko, Jolanta
- Subjects
HOME hemodialysis ,HEMODIALYSIS ,PERITONEAL dialysis ,HEMODIALYSIS patients ,RENAL replacement therapy ,SOCIAL distancing - Abstract
Introduction: Home dialysis in Poland is restricted to the peritoneal dialysis (PD) modality, with the majority of dialysis patients treated using in-centre haemodialysis (ICHD). Home haemodialysis (HHD) is an additional home therapy to PD and provides an attractive alternative to ICHD that combines dialysis with social distancing; eliminates transportation needs; and offers clinical, economic, and quality of life benefits. However, HHD is not currently provided in Poland. This review was performed to provide an overview of the main barriers to the introduction of a HHD programme in Poland. Main findings: The main high-level barrier to introducing HHD in Poland is the absence of specific health legislation required for clinician prescribing of HHD. Other barriers to overcome include clear definition of reimbursement, patient training and education (including infrastructure and experienced personnel), organisation of logistics, and management of complications. Partnering with a large care network for HHD represents an alternative option to payers for the provision of a new HHD service. This may reduce some of the barriers which need to be overcome when compared with the creation of a new HHD service and its supporting network due to the pre-existing infrastructure, processes, and staff of a large care network. Conclusions: Provision of HHD is not solely about the provision of home treatment, but also the organisation and definition of a range of support services that are required to deliver the service. HHD should be viewed as an additional, complementary option to existing dialysis modalities which enables choice of modality best suited to a patient's needs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Type of arteriovenous fistula, NYHA class and apelin in hemodialyzed patients
- Author
-
Malyszko, Jolanta, Kozminski, Piotr, Malyszko, Jacek, and Mysliwiec, Michal
- Published
- 2011
- Full Text
- View/download PDF
7. Labile plasma iron levels in chronic hemodialysis patients treated by intravenous iron supplementation.
- Author
-
Bnaya, Alon, Shavit, Linda, Malyszko, Jacek S., Malyszko, Jolanta, and Slotki, Itzchak
- Subjects
HEMODIALYSIS patients ,INTRAVENOUS therapy ,PATIENT monitoring ,PATHOLOGICAL laboratories ,FERRITIN - Abstract
The increased usage of intravenous iron in hemodialysis patients during recent years has led to increasing concern over the potential development of iron overload. Current methods for detecting iron overload, transferrin saturation, and serum ferritin are neither sensitive nor specific. Labile plasma iron (LPI) represents a component of nontransferrin‐bound iron and may be a more accurate indicator of impending iron overload. We studied whether LPI measured can serve as an early indicator of impending iron overload and mortality in hemodialysis patients. Chronic hemodialysis patients from two medical centers in Israel and Poland who received intravenous iron were included. Baseline clinical and laboratory parameters were recorded. LPI was measured before and 48 hours after a single IV administration. Correlation of positive LPI with laboratory parameters and 2‐year mortality was evaluated. One hundred and one hemodialysis patients were included in the study. LPI became positive post‐administration in 18 (17.8%) patients. Ferritin levels >526 ng/mL and monthly iron doses >250 mg were associated with positive LPI after intravenous iron. At a 2‐year follow‐up, higher mortality was observed in the positive LPI group (61.1% compared to 25.3%, P ≤.05), although this effect was not statistically significant after multivariate adjustment. A substantial number of hemodialysis patients have positive LPI after intravenous iron administration. LPI positively correlates with laboratory parameters that are currently in routine clinical use for detecting iron overload and with higher intravenous iron dose. Further studies should be conducted to establish the clinical implications of LPI monitoring in hemodialysis patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. The Serum Concentration of Anti-Aging Proteins, Sirtuin1 and αKlotho in Patients with End-Stage Kidney Disease on Maintenance Hemodialysis.
- Author
-
Zbroch, Edyta, Bazyluk, Angelika, Malyszko, Jolanta, Koc-Zorawska, Ewa, Rydzewska-Rosolowska, Alicja, Kakareko, Katarzyna, and Hryszko, Tomasz
- Subjects
CHRONIC kidney failure ,AGING prevention ,DISEASES ,HEMODIALYSIS ,CARDIAC hypertrophy - Abstract
Introduction: Sirtuin1 (SIRT1) acts as an anti-aging protein due to anti-apoptotic, anti-oxidative and anti-inflammatory effect and is implicated in several diseases including diabetes or cardiovascular problems. SIRT1 renal overexpression indicates oxidative stress. Similarly, αKlotho was primarily exposed as anti-aging factor. It is primary produced in kidney. It's deficiency is associated with progression of chronic kidney disease and heart disorders. Purpose: The aim of the study was to assess the serum concentration of sirtuin1 and αKlotho in hemodialysis (HD) patients compared to healthy volunteers in regard to age, blood pressure control, residual kidney function (RKF), diabetes, cardiovascular disease, dialysis vintage and type of dialyzer. Patients and Methods: The serum level of SIRT1 and αKlotho was evaluated using ELISA tests in 103 HD patients, median age 67 years and in 21 volunteers. Blood pressure, RRF, echocardiography and dialysis parameters were assessed. HD group was divided according to the presence/absence of RKF. Results: The serum SIRT1 level was higher (28.4 vs 2.71ng/mL, p< 0.0001) and αKlotho was lower (433.9 vs 756.6pg/mL, p< 0.0001) in HD then in control group. αKlotho was lower in those without RKF (387.2 vs 486.2pg/mL, p=0.028). SIRT1 positively correlated with hemodialysis vintage. αKlotho negatively correlated with left ventricular posterior wall thickness. There was no significant relationship between SIRT1 and αKlotho level and age, blood pressure control, type of dialyzer, Kt/V and diabetes. Multivariate analysis revealed association of SIRT1 with ejection fraction (B − 0.72; p=0.32). Conclusion: Elevated SIRT1 and lower αKlotho concentration are associated with impaired kidney function. The decrease in levels of αKlotho may also indicate heart hypertrophy in hemodialysis patients. The role of anti-aging proteins, particularly SIRT1 as biomarkers/predictors of oxidative stress, inflammation and cardiovascular diseases need further examination. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison.
- Author
-
Zawierucha, Jacek, Malyszko, Jolanta, Malyszko, Jacek S., Prystacki, Tomasz, Marcinkowski, Wojciech P., and Dryl-Rydzynska, Teresa
- Subjects
HYPERPARATHYROIDISM treatment ,DRUGS ,VITAMIN D ,PARATHYROID hormone ,HEMODIALYSIS ,HYPERCALCEMIA - Abstract
Introduction: Secondary hyperparathyroidism (sHPT) is a common hormonal complication of chronic kidney disease. There are several therapeutic options for sHPT management aiming at calcium-phosphorus balance normalization and decrease of parathormone secretion. Objectives: The aim of this retrospective, observational study was the outcome assessement of three most common therapeutic strategies of secondary hyperparathyroidism treatment with vitamin D receptor activator-paricalcitol, calcimimetic-cinacalcet or both agents administered together during in 12-months period. Methods: One hundred and thirty-one haemodialysed patients with uncontrolled parathyroid hormone secretion have been treated with paricalcitol administered intravenously (group PAR−60 patients) or cinacalcet per os (group CIN−50 patients). The last group (group PAR+CIN−21 patients) received paricalcitol i.v. and oral cinacalcet administered simultaneously. Results: In all groups, the iPTH level decreased significantly, however in group 1 treated with paricalcitol administered intravenously iPTH level decrease was greater than in group 2 treated with cinacalcet and in group 3 treated with paricalcitol and cinacalcet in parallel. The most substantial change of iPTH level was noticed after 3-months of observation. After this period the iPTH level was stabilized and maintained till the end of observation. Safety level of all strategies was comparable. No severe hypercalcemia or hypocalcemia was observed during the whole period of observation. Conclusions: The results of observation show significant advantage of intravenous paricalcitol treatment. Complementing cinacalcet therapy with paricalcitol does not improve treatment outcomes. In case of unsatisfactory results after 3-months treatment, potential continuation should be considered carefully. Among three available therapeutic options, the treatment with paricalcitol i.v. should be considered in all haemodialysed patients with inadequate control of serum PTH level. The second option—with cinacalced administered orally should be considered in PD patients and when severe hypercalcemia occurs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council.
- Author
-
Zoccali, Carmine, Arici, Mustafa, Blankestijn, Peter J, Bruchfeld, Annette, Capasso, Giovambattista, Fliser, Danilo, Fouque, Denis, Goumenos, Dimitrios, Ketteler, Markus, and Malyszko, Jolanta
- Subjects
HEMODIALYSIS ,KIDNEY transplantation ,INFORMATION sharing ,PROFESSIONAL education ,TREATMENT of chronic kidney failure - Abstract
Scientific societies are increasingly seen as central to the advancement of information sharing and collaboration among scientists and clinical investigators for the progress of medical research and the promotion of education, professional competence, integrity and quality studies. To more effectively serve the practicing nephrologists and investigators dedicated to renal science, the Council of the European Renal Association and European Dialysis and Transplantation Association (ERA-EDTA) reorganized and integrated the various activities of the society into two branches, the Clinical Nephrology Governance branch and the Renal Science branch. New affordable initiatives to promote research, education and professional development and to advocate for the recognition of chronic kidney disease as a major public health issue at the European level will be put in place and/or potentiated in the new organizational frame. Educational initiatives will be espoused to Continuous Professional Development and, starting from 2019, 14 Education & Continuous Professional Development courses will be held covering the full range of knowledge areas of modern nephrology. Consolidation and development is the short- and medium-term mantra of the ERA-EDTA. The society has a rich portfolio of successful activities and brilliant, creative scientists among itsmembers. Integrating the various activities of the ERA-EDTA and treasuring the expertise and wisdom of its most accomplished members will facilitate collaborative research, education and its public impact at large. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Comorbidities on kidney transplantation waiting list relative to the status of the potential recipient.
- Author
-
Malyszko, Jolanta, Dryl-Rydzynska, Teresa, Marcinkowski, Wojciech, Prystacki, Tomasz, and Malyszko, Jacek S.
- Subjects
- *
KIDNEY transplantation , *TRANSPLANTATION of organs, tissues, etc. , *KIDNEY diseases , *HEMODIALYSIS , *CHRONIC kidney failure , *KIDNEY failure - Published
- 2018
- Full Text
- View/download PDF
12. Iron metabolism in hemodialyzed patients - a story half told?
- Author
-
Malyszko, Jolanta, Koc-Zorawska, Ewa, Levin-Iaina, Nomy, Slotki, Itzchak, Matuszkiewicz-Rowinska, Joanna, Glowinska, Irena, and Malyszko, Jacek S.
- Subjects
- *
C-reactive protein , *NATIVE element minerals , *SIDEROPHILE elements , *METABOLIC regulation , *PATIENT acceptance of health care , *PATIENT compliance , *THERAPEUTICS - Abstract
Introduction: All living organisms have evolved sophisticated mechanisms to maintain appropriate iron levels in their cells and within their body. Recently our understanding of iron metabolism has dramatically increased. Overt labile plasma iron (LPI) represents a component of non-transferrin bound iron (NTBI) that is both redox active and chelatable, capable of permeating into organs and inducing tissue iron overload. The LPI measures the iron-specific capacity of a given sample to produce reactive oxygen species. We studied for the first time NTBI correlations with markers of iron status and inflammation in prevalent hemodialyzed patients. Material and methods: Complete blood count, urea, serum lipids, fasting glucose, creatinine, ferritin, serum iron, total iron binding capacity (TIBC) were studied by standard laboratory method. The NTBI was assessed commercially available kits from Aferrix Ltd in Tel Aviv, Israel. A test result of 0.6 units of LPI or more indicates a potential for iron-mediated production of reactive oxygen species in the sample. Results: Patients with LPI units ⩾ 0.6 had higher serum iron, erythropoiesis stimulating agents (ESA) dose, ferritin, high-sensitivity C-reactive protein (hsCRP), hepcidin and lower hemojuvelin. In hemodialyzed patients NTBI correlated with hsCRP (r = 0.37, p < 0.01), ferritin (r = 0.41, p < 0.001), IL-6 (r = 0.43, p < 0.001). In multivariate analysis predictors of NTBI were hemoglobin and alkaline phosphatase, explaining 58% of the variability Conclusions: Elevated NTBI in HD may be due to disturbed iron metabolism. Anemia and liver function might also contribute to the presence of NTBI in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Circulating Levels of Renalase, Norepinephrine, and Dopamine in Dialysis Patients.
- Author
-
Zbroch, Edyta, Koc-Zorawska, Ewa, Malyszko, Jolanta, Malyszko, Jacek, and Mysliwiec, Michal
- Subjects
NORADRENALINE ,DOPAMINE ,HEMODIALYSIS patients ,BLOOD pressure ,PERITONEAL dialysis ,CATECHOLAMINES ,KIDNEY diseases ,PATHOLOGICAL physiology ,NEUROLOGICAL disorders - Abstract
Background: hRenalase may degrade catecholamines and regulate sympathetic tone and blood pressure (BP). The aim of the study was to assess dopamine (DA), norepinephrine (NE), and renalase in 75 hemodialysis (HD) and 26 peritoneal dialysis (PD) patients and their correlations with heart rate (HR), BP, a type of hypotensive therapy, and residual renal function. Methods: Renalase, DA, NE were studied using commercially available assays. Results: Renalase and NE were higher and DA was lower in dialyzed groups comparing to healthy volunteers. Hemodialysis patients had lower NE and higher renalase level. Norepinephrine was higher in anuric patients in HD group. Renalase correlated with dialysis vintage and inversely with residual diuresis. Dopamine correlated with residual diuresis in the whole study cohort, with HR in PD patients, with renalase in HD patients. Norepinephrine correlated with aortic diameter in PD patients. Norepinephrine was significantly higher in patients with coronary artery disease (CAD) in HD group. Hemodialysis population with CAD had lower NE and higher DA and renalase level than their PD counterparts. In the follow up, 27% of HD group died. Cardiac death was diagnosed in 17% and there was higher renalase level than in noncardiac death. Conclusions: Elevated level of circulating renalase in dialysis patients is rather related to kidney function and the sympathetic nervous system hyperactivity found in this population. The real excess of renalase in the pathogenesis of cardiovascular disorders in patients with chronic kidney disease still remains to be proven. If confirmed, it may give a new way for pathophysiological therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. Renalase, a Novel Enzyme Involved in Blood Pressure Regulation, Is Related to Kidney Function but Not to Blood Pressure in Hemodialysis Patients.
- Author
-
Zbroch, Edyta, Malyszko, Jolanta, Malyszko, Jacek S., Koc-Zorawska, Ewa, and Mysliwiec, Michal
- Subjects
- *
ANTIHYPERTENSIVE agents , *REGULATION of blood pressure , *HYPERTENSION , *KIDNEY diseases , *KIDNEY function tests , *HEMODIALYSIS patients , *PATIENTS - Abstract
Renalase, secreted by the kidney, degrades catecholamines and may play a role in the regulation of sympathetic tone and blood pressure. The aim of this study was to assess serum renalase levels in hemodialysis patients and their relationship to blood pressure control, type of antihypertensive therapy and the presence of residual renal function. Results: The mean serum renalase in the study cohort was significantly higher than in the control group (27.53 ± 7.18 vs. 3.86 ± 0.73 p,g/ml,p< 0.001).The serum renalase concentration was significantly lower in patients with residual renal function when compared to the anuric patients. The type of hypotensive treatment ((3-blockers, ACE inhibitors or AT1 receptor blockers) did not affect renalase levels. There was a significant inverse correlation between the serum renalase and age (r = -0.28, p = 0.023) and residual renal function (r = -0.327, p = 0.001). Renalase was not related to blood pressure, heart rate or hemodialysis vintage. Conclusion: Elevated renalase levels in HD patients may be due to impaired kidney function. Further studies are needed to prove or disprove the possible role of renalase in the pathogenesis of hypertension in patients with kidney diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Renalase, Stroke, and Hypertension in Hemodialyzed Patients.
- Author
-
Malyszko, Jolanta, Koc-Zorawska, Ewa, Malyszko, Jacek S, Kozminski, Piotr, Zbroch, Edyta, and Mysliwiec, Michal
- Subjects
- *
STROKE , *HYPERTENSION , *HEMODIALYSIS , *KIDNEY diseases , *ECHOCARDIOGRAPHY , *SERUM , *REGRESSION analysis - Abstract
Introduction: Hypertension and kidney disease have been associated with increased incidence of stroke. Renalase, a newly discovered hormone, is secreted by the kidney and circulates in blood. The aim of this study was to assess possible correlations between renalase, blood pressure, stroke, and cardiovascular status in prevalent hemodialyzed patients. Methods: Renalase was assessed using commercially available assay. Echocardiography was performed in each patient. Results: Serum renalase was significantly lower in patients with a history of stroke (21%) than in patients without it. Similarly, renalase was significantly lower in hypertensive patients (82%) when compared with normotensives. Serum renalase correlated with creatinine, residual renal function, and transferrin saturation. The only predictor of renalase in multiple regression analysis was the presence of hypertension explaining 90% of the renalase variations. Conclusions: Our preliminary results suggest that renalase, probably due to the sympathetic nervous system hyperactivity, could be associated with hypertension and cardiovascular complications, including stroke in hemodialyzed patients. However, further studies are needed to establish the possible role of renalase in these complications. Renalase is 'a new postulated therapeutic target.' [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
16. Serum Hemojuvelin and Hepcidin Levels in Chronic Kidney Disease.
- Author
-
Rumjon, Adam, Sarafidis, Pantelis, Brincat, Stephan, Musto, Rebecca, Malyszko, Jolanta, Bansal, Sukhvinder S., and Macdougall, Iain C.
- Abstract
Background: Hemojuvelin (HJV) has recently emerged as one of a number of significant regulators of iron homeostasis and hepcidin expression. Recently, an immunoassay has been developed to measure circulating levels of soluble HJV (sHJV). The aim of this study was to measure serum hepcidin and sHJV levels in a chronic kidney disease (CKD) population. Methods: A total of 93 patients participated in the study (31 hemodialysis, 31 non-dialysis, 31 transplant recipients), and were matched for age and gender. Serum samples were taken for measurement of hepcidin-25 and sHJV, along with standard hematological, biochemical and inflammatory markers, and univariate/multivariate analyses were performed. Results: Serum sHJV levels were markedly elevated in the hemodialysis patients (2,619 ± 1,445 ng/ml) compared to the CKD (590 ± 344 ng/ml) and transplant recipients (870 ± 638 ng/ml) (p < 0.001), normal range 370-890 ng/ml. There was a strong correlation between serum ferritin and sHJV, which remained after adjustment for potential confounders (beta 0.92, p < 0.001). In the univariate analysis, sHJV levels correlated with serum hepcidin but this was not evident in the multivariate analysis. No associations were seen between sHJV and markers of inflammation or eGFR. Conclusions: sHJV is elevated in hemodialysis patients compared to non-dialysis CKD patients. There was no association between sHJV and eGFR (in the non-dialysis groups), suggesting that factors other than decreased renal clearance are responsible for the high sHJV levels. The strong association between sHJV and ferritin suggests an interdependent relationship, although further studies are required to elucidate the possible mechanism(s) for this. Copyright © 2012 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
17. Renal Anemia Treatment with ESA in Hemodialysis Patients in Relation to Early versus Late Referral in Everyday Clinical Practice in Central and Eastern European Countries: Baseline Data.
- Author
-
Malyszko, Jolanta, Drozdz, Maciej, Zolkiewicz, Agnieszka, and Rutkowski, Boleslaw
- Subjects
- *
RENAL anemia , *HEMODIALYSIS , *CHRONIC kidney failure , *MEDICAL referrals , *THERAPEUTICS - Abstract
The aim of the study was to collect retrospective data on renal anemia management, comorbidities and prospective data on 12-month standard care erythropoiesis-stimulating agent (ESA) therapy used in 398 hemodialyzed patients in selected Central and Eastern European countries (50 centers in 3 countries). Patients were divided into three groups according to ESA therapy start: group A-ESA (after start of hemodialysis, HD), B-ESA (within 3 months from start of HD), C-ESA (more than 3 months before HD). At the chronic kidney disease diagnosis, hemoglobin in all patients was 10.3 ± 2.3 g/dl; however, ferritin, iron, TSAT were within reference limits. Early ESA therapy (C) was administered to 10% of patients only. 47% of patients received ESA after start of dialysis. Before study, the mean weekly ESA dose in group C was statistically lower than in groups B and A (p < 0.001). At baseline visit, hemoglobin in group A patients was slightly lower than in group B and C patients (p = 0.025). In conclusion, in Central and Eastern European countries renal anemia therapy with ESA starts shortly before or after start of HD. This highlights important differences in standard care in Eastern Europe. However, paradoxically, due to the tight reimbursement policy we foresee the clinical implications of the TREAT trial for the chronic kidney disease population. Copyright © 2011 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Copeptin and Its Relation to Arteriovenous Fistula (AVF) Type and NYHA Class in Hemodialysis Patients.
- Author
-
Malyszko, Jolanta, Levin-Iaina, Nomy, Malyszko, Jacek S., Kozminski, Piotr, Koc-Zorawska, Ewa, and Mysliwiec, Michal
- Subjects
- *
ARTERIOVENOUS fistula , *HEMODIALYSIS patients , *VASOPRESSIN , *BIOMARKERS , *HEART failure , *COHORT analysis - Abstract
Copeptin is cosynthesized with vasopressin, also known as anti-diuretic hormone, with similar plasma levels. In the past 2 years, copeptin has been studied as a diagnostic and prognostic marker in infections and other diseases. In patients with decompensated heart failure, copeptin was an accurate prognostic marker for mortality. Cardiovascular disease is a major contributor to the mortality and morbidity in chronic kidney disease. Creation of an arteriovenous fistula (AVF) might contribute to the development or worsening of congestive heart failure (CHF). The aim of the study was to assess associations between copeptin, New York Heart Association (NYHA) class, and the location of the AVF in hemodialysis (HD) patients. The cross-sectional study was performed on a cohort of 93 clinically stable HD patients. Patients with proximal AVF tend to be older, with decreased renal residual function and increased NYHA functional class. These patients were also highly anemic, had more acidosis, and had increased high-sensitivity C-reactive protein along with increased copeptin and NT-proBNP levels. These changes were also associated with significant changes in all intra-cardiac dimensions, including right ventricle, both atria, and intraventricular septum and increase in end-systolic and end-diastolic left ventricular intra-cardiac dimensions. In multiple logistic regression analysis, the only associate of copeptin was NYHA functional class. Copeptin level in HD patients depends on cardiac function and it might be involved in the pathophysiology of cardiovascular disease in these patients. Proximal AVF creation might contribute to the development or worsening of CHF in HD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
19. Mechanism of endothelial dysfunction in chronic kidney disease
- Author
-
Malyszko, Jolanta
- Subjects
- *
KIDNEY diseases , *ENDOTHELIUM , *DIABETIC nephropathies , *NITRIC oxide , *HEMODIALYSIS , *CYTOKINES , *ATHEROSCLEROSIS - Abstract
Abstract: Endothelium is the largest organ in the body strategically located between the wall of blood vessels and the blood stream. The human body contains approximately 1013 endothelial cells weighing approximately 1kg, and covering a surface area of 4000 to 7000m2 equivalent to the soccer playground. Hypertension and shear stress, inflammation, diabetes-associated factors such as advanced glycated end products, and uremic toxins are some of the prevalent risk factors of endothelial dysfunction in chronic kidney disease. In renal failure endothelial dysfunction and atherosclerosis are almost universal, as well as cardiovascular complications. Endothelial cell damage or injury is invariably associated with such clinical conditions as thrombosis, hypertension, renal failure and atherosclerosis and may be also responsible for accelerated atherosclerosis in patients with chronic renal failure. Traditional risk factor cannot explain the high prevalence and incidence of cardiovascular disease in chronic kidney disease, therefore other non-traditional risk factors such as endothelial dysfunction, oxidative stress or insulin resistance have increasingly been studied. In this review paper mechanism of endothelial dysfunction, including the role of nitric oxide pathway, adipocytokines and hemodialysis-induced endothelial dysfunction is discussed. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
20. Possible Relationship between Neutrophil Gelatinase-Associated Lipocalin, Hepcidin, and Inflammation in Haemodialysed Patients.
- Author
-
Malyszko, Jolanta, Malyszko, Jacek S., Kozminski, Piotr, Koc-Zorawska, Ewa, Mysliwiec, Michal, and Macdougall, Iain
- Subjects
- *
NEUTROPHILS , *HEMODIALYSIS patients , *SIDEROPHORES , *LIVER cells , *IRON metabolism , *TRANSFERRIN - Abstract
Background: Neutrophil gelatinase-associated lipocalin (NGAL) binds small, iron-carrying molecules – siderophores. On the other hand, hepcidin is a small defensin-like peptide produced by hepatocytes, modulated in response to anaemia, hypoxia, or inflammation. We tested the hypothesis that NGAL may be related to hepcidin, not only to iron metabolism, in 182 prevalent haemodialysed patients. Methods: Iron status (iron, total iron-binding capacity, ferritin, total saturation of transferrin, TSAT), complete blood count, creatinine, albumin, serum lipids were assessed using standard laboratory methods. Soluble receptor of transferrin, high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor-α, interleukin-6, prohepcidin, hepcidin and NGAL were measured in serum using commercially available kits. Results: Serum NGAL, prohepcidin, hepcidin levels were significantly higher in haemodialysed patients over healthy volunteers (579.11 ± 213.95 vs. 78.43 ± 32.21 ng/ml, p < 0.001, 320.54 ± 182.65 vs. 98.65 ± 34.32 ng/ml, p < 0.01, 155.30 ± 94.05 vs. 23.65 ± 12.76 ng/ml, p < 0.001, respectively). Serum NGAL correlated strongly with residual renal function (r = –0.54, p < 0.001), Kt/V (r = 0.41, p < 0.001), hepcidin (r = –0.28, p < 0.01), serum creatinine (r = 0.63, p < 0.001), iron (r = 0.25, p < 0.01), TSAT (r = 0.30, p < 0.001), ferritin (r = 0.33, p < 0.001), hsCRP (r = 0.32, p < 0.001). In multiple regression analysis, residual renal function, hepcidin, creatinine and hsCRP were predictors of serum NGAL in haemodialysed patients. Conclusions: NGAL is highly induced in dialysed patients. NGAL could reflect both kidney function and iron metabolism. Taking into account the antimicrobial properties of NGAL, further studies are needed to address the role of NGAL in iron metabolism and inflammation in renal failure. Copyright © 2010 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
21. Effects of dialyzer reuse on dialysis adequacy, anemia control, erythropoieting-stimulating agents use and phosphate level.
- Author
-
Malyszko, Jolanta, Milkowski, Andrzej, Benedyk-Lorens, Ewa, and Dryl-Rydzynska, Teresa
- Subjects
- *
HEMODIALYZERS , *HEMODIALYSIS , *ANEMIA prevention - Abstract
A letter to the editor is presented regarding the study which focuses on the impact of the reuse of dialyzer on the adequacy of dialysis, anemia control, and erythropoieting-stimulating agents (ESA).
- Published
- 2016
- Full Text
- View/download PDF
22. Neutrophil Gelatinase-Associated Lipocalin in Dialyzed Patients Is Related to Residual Renal Function, Type of Renal Replacement Therapy and Inflammation.
- Author
-
Malyszko, Jolanta, Malyszko, Jacek S., Koc-Zorawska, Ewa, Kozminski, Piotr, and Mysliwiec, Michal
- Subjects
- *
HEMODIALYSIS patients , *TREATMENT of chronic kidney failure , *DIALYSIS (Chemistry) , *BLOOD filtration , *KIDNEY disease treatments - Abstract
Neutrophil gelatinase-associated lipocalin (NGAL) has recently been proved useful in the quantitation of chronic kidney disease. A cross-sectional study was performed to assess NGAL in serum, urine and ultrafiltrate in relation to the type of renal replacement therapy and NGAL correlations with renal function and markers of inflammation. Methods: NGAL, hsCRP, TNFα, and IL-6 were measured using commercially available kits in 200 patients on hemodialysis (HD), 17 on hemodiafiltration (HDF). Results: Patients on HDF had lower serum NGAL than those on HD. In hemodialyzed patients with residual renal function, serum NGAL was significantly lower than in anuric patients. NGAL was significantly higher in patients dialyzed on modified cellulose dialyzers versus polysulphone dialyzers. NGAL correlated with age, residual renal function, hsCRP, IL-6, TNF-α, time on HD, ferritin, TSAT, creatinine, urea, urea reduction ratio, and Kt/V in hemodialyzed patients. In multiple regression analysis, residual renal function and hsCRP were predictors of NGAL in hemodialyzed patients. NGAL correlated with hsCRP and creatinine in HDF patients. Conclusions: Residual renal function seems to play a pivotal role in NGAL levels in dialyzed patients. Low-grade inflammation, more pronounced in anuric patients may also contribute to elevated NGAL. Removal of NGAL with ultrafiltrate may also partially explain its lower concentration after dialysis. Copyright © 2010 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
23. Serum Prohepcidin and Hepcidin in Hemodialyzed Patients Undergoing Iron Therapy.
- Author
-
Malyszko, Jolanta, Malyszko, Jacek S., and Mysliwiec, Michal
- Subjects
- *
HEMODIALYSIS , *SERUM , *IRON , *TRANSFERRIN , *KIDNEY diseases - Abstract
Hepcidin is the predominant negative regulator of iron absorption in the small intestine, iron transport across the placenta, and iron release from the macrophages. Iron supplementation is often introduced in dialyzed patients to replete or to maintain iron stores, particularly in patients treated with erythropoietin-stimulating agents. The aim of this study was to assess hepcidin levels in 12 hemodialyzed (HD) patients (6 females, 6 males, mean age 64 years, mean time on HD 36 months) before and after intravenous iron therapy. Prohepcidin and hepcidin were studied using commercially available kits from DRG Instruments GmbH, Marburg, Germany (ELISA method), and Bachem, St. Helens, UK (RIA method). Soluble receptor of transferrin was studied using a kit from R&D, Abington, UK. We found a significant rise in hemoglobin concentration, hematocrit, ferritin, serum iron, transferrin saturation and a fall in soluble receptor of transferrin. Serum hepcidin and prohepcidin as well as urinary prohepcidin increased significantly after the therapy. In conclusion, hepcidin levels are influenced by iron supplementation in HD patients. Further examinations of hepcidin as a marker of iron deficiency using new validated measurement techniques are required. It remains to be seen if assay of hepcidin will be of help in identifying patients unresponsive to oral iron or requiring intravenous iron supplementation. Copyright © 2009 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
24. Current Status of Renal Anemia Pharmacotherapy—What Can We Offer Today.
- Author
-
Borawski, Bartłomiej, Malyszko, Jacek Stanislaw, Kwiatkowska, Marlena, and Malyszko, Jolanta
- Subjects
ANEMIA ,TREATMENT effectiveness ,DRUG synthesis ,CHRONIC kidney failure ,ANEMIA treatment - Abstract
Chronic kidney disease (CKD) is one of the fastest-growing major causes of death internationally. Better treatment of CKD and its complications is crucial to reverse this negative trend. Anemia is a frequent complication of CKD and is associated with unfavorable clinical outcomes. It is a devastating complication of progressive kidney disease, that negatively affects also the quality of life. The prevalence of anemia increases in parallel with CKD progression. The aim of this review is to summarize the current knowledge on therapy of renal anemia. Iron therapy, blood transfusions, and erythropoietin stimulating agents are still the mainstay of renal anemia treatment. There are several novel agents on the horizon that might provide therapeutic opportunities in CKD. The potential therapeutic options target the hepcidin–ferroportin axis, which is the master regulator of iron homeostasis, and the BMP-SMAD pathway, which regulates hepcidin expression in the liver. An inhibition of prolyl hydroxylase is a new therapeutic option becoming available for the treatment of anemia in CKD patients. This new class of drugs stimulates the synthesis of endogenous erythropoietin and increases iron availability. We also summarized the effects of prolyl hydroxylase inhibitors on iron parameters, including hepcidin, as their action on the hematological parameters. They could be of particular interest in the out-patient population with CKD and patients with ESA hyporesponsiveness. However, current knowledge is limited and still awaits clinical validation. One should be aware of the potential risks and benefits of novel, sophisticated therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Femoral localization and higher ultrafiltration rate but not concentration of heparin used for canal locking of hemodialysis catheter are negative predictors for its malfunction.
- Author
-
Brzosko, Szymon, Hryszko, Tomasz, Malyszko, Jolanta, Malyszko, Jacek Stanisław, Mazerska, Maria, Myśliwiec, Michal, Malyszko, Jacek Stanisław, and Myśliwiec, Michal
- Subjects
CATHETERIZATION ,CATHETERS ,FEMORAL vein ,HEMODIALYSIS ,HEPARIN ,JUGULAR vein ,LONGITUDINAL method ,PROPORTIONAL hazards models ,MEDICAL equipment reliability ,PHARMACODYNAMICS ,EQUIPMENT & supplies - Abstract
Background/Aim: Non-tunneled, temporal hemodialysis (HD) catheters are commonly used as short-term vascular access for the HD procedure. One of their late complications is thrombotic occlusion of the catheter ensuing in their malfunction. A heparin lock is conventionally used for maintaining the patency of the catheter. The aim of the study was to evaluate the influence of heparin concentration used for locking the catheter canals (5,000 vs. 2,500 IU/ml) and some other clinical and laboratory variables at the time of temporal HD catheter functioning. Methods: Catheter malfunction was defined as the inability to attain and maintain a blood flow of at least 150 ml/min. 174 consecutive HD catheters inserted into jugular or femoral veins (114 patients) were followed up and remained in use for a total of 3,284 days. Results: Catheter thrombosis occurred in 53 cases (30.5%) during the study period, giving an overall rate of 16 episodes per 1,000 catheter-days at risk. In univariate Cox proportional hazard analysis, predictors of catheter dysfunction were: femoral localization (HR 4.92, 95% CI 4.30–5.50), acute renal failure (HR 1.75, 95% CI 1.18–2.32), higher mean ultrafiltration (UF) (HR 1.31, 95% CI 0.99–1.63) and higher concentration of hemoglobin (HR 1.15, 95% CI 0.99–1.33). The concentration of heparin used for canal locking did not influence the time of catheter functioning (HR 1.1, p = 0.7). In multivariate Cox proportional hazard analysis (χ
2 = 38.5, d.f. = 4, p < 0.0001) the remaining statistically independent predictors of catheter malfunction were: femoral localization (HR 5.94, 95% CI 5.27–6.61, p < 0.0001) and higher UF (HR 1.60, 95% CI 1.24–1.94, p < 0.01). Conclusions: A lower concentration of heparin (2,500 IU/ml) prevents catheter thrombosis as effectively as a standard one (5,000 IU/ml). Femoral localization of HD catheters and higher UF during the HD procedure are the factors predisposing for catheter malfunction. Copyright © 2007 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
26. Elevated resistin is related to inflammation and residual renal function in haemodialysed patients.
- Author
-
MALYSZKO, JOLANTA, MALYSZKO, JACEK S, KOZMINSKI, PIOTR, PAWLAK, KRYSTYNA, and MYSLIWIEC, MICHAL
- Subjects
- *
INFLAMMATION , *HEMODIALYSIS patients , *THROMBOSIS , *ATHEROSCLEROSIS , *CYTOKINES , *KIDNEY abnormalities , *MEDICAL research - Abstract
Aim: Resistin is an adipocytokine that recently generated much interest. Because of the fact that inflammation, endothelial cell damage or injury is invariably associated with such clinical conditions as thrombosis, atherosclerosis and their major clinical consequences, that is, cardiovascular disease and resistin play a role in linking inflammation and cardiovascular disease, the aim of the study was to assess resistin in correlation with markers of inflammation, endothelial cell injury and residual renal function in haemodialysed (HD) patients. Methods: We assessed resistin, markers of coagulation: thrombin-antithrombin complexes (TAT), prothrombin fragments 1+2; fibrinolysis: tPA, plasminogen activator inhibitor type 1, plasmin-antiplasmin complexes (PAP); endothelial function/injury: von Willebrand factor (vWF), thrombomodulin, intracellular adhesion molecule (ICAM); inflammation: high sensitivity C-reactive protein (hsCRP), tumour necrosis factor alpha and interleukin-6 (IL-6). Results: Healthy volunteers and HD patients did not differ significantly regarding age, leucocyte count, serum iron, aspartate and alanine aminotransferases activities, calcium, cholesterol, tPA concentration. Triglycerides, CRP (assessed by high sensitivity method), phosphate, urea, creatinine, IL-6, tumour necrosis factor alpha, vWF, prothrombin fragments 1+2, TAT, PAP, thrombomodulin, ICAM, plasminogen activator inhibitor type 1 and resistin, were elevated in HD patients when compared with the control group. Serum albumin, total protein, haemoglobin and haematocrit were significantly lower in HD patients when compared with the control group. In HD patients with hsCRP 0e; 6 mg/L, resistin, IL-6, vWF and F1+2 were significantly higher, whereas tPA was significantly lower than in patients with hsCRP < 6 mg/L. Moreover, HD patients with residual renal function have significantly lower resistin when compared with patients without it. Resistin was significantly higher in diabetics. In HD patients, resistin correlated significantly, in univariate analysis, with calcium, phosphate, PTH, TIBC, vWF residual renal function, urea, hsCRP, IL-6 and tended to correlate with tPA and ferritin. In the healthy volunteers, resistin was related to IL-6 and hsCRP. In multiple regression analysis, resistin was independently related to hsCRP, IL-6, residual renal function in HD patients. Conclusion: Elevated resistin related to markers of inflammation may represent a novel link between inflammation and adipocytokines in HD patients. Impaired renal function and inflammation are responsible for elevated resistin in HD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
27. Basilic Vein Transposition in the Forearm for Secondary Arteriovenous Fistula.
- Author
-
Glowinski, Jerzy, Glowinska, Irena, Malyszko, Jolanta, and Gacko, Marek
- Subjects
VEIN surgery ,ARTERIOVENOUS fistula ,FOREARM ,VASCULAR resistance ,PROPORTIONAL hazards models ,DATA analysis software ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator - Abstract
Radiocephalic (RC) fistulae remain the first choice access for hemodialysis. The antecubital fossa is recommended as the next site. However, for some patients a basilic vein can be used to create an arteriovenous (av) fistula. We report a series of patients where the forearm basilic vein served as an alternative conduit for secondary procedures. Over an 8-year period, 30 patients who had a failed RC fistula underwent a basilic vein transposition. The immediate results were satisfactory. All fistulas were successfully cannulated. Cumulative patency was 93% after 1 year, 78% after 2 years, and 55% after 3 years. No ischemic or infectious complications were noted during the study period. The use of the forearm basilic vein to create a native av fistula appears to be a good alternative to procedures in the antecubital fossa or upper arm, thus preserving more proximal veins for future use. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
28. Risk Factors of Nontunneled Noncuffed Hemodialysis Catheter Malfunction.
- Author
-
Hryszko, Tomasz, Brzosko, Szymon, Mazerska, Maria, Malyszko, Jolanta, and Mysliwiec, Michal
- Subjects
HEMODIALYSIS complications ,CATHETER ablation ,JUGULAR vein ,FEMORAL vein ,VASCULAR diseases ,BACTEREMIA - Abstract
Background: The use of noncuffed nontunneled central venous catheters is a widely accepted method of gaining temporary vascular access for hemodialysis. Malfunction and bacteremia are the main factors limiting catheter survival. Methods: We followed up prospectively 73 hemodialysis catheters (HC) (40 internal jugular, 33 femoral) in order to establish factors influencing HC malfunction. HC malfunction was defined as a catheter that was unable to attain and maintain blood flows of at least 150 ml/min. 73 HC were used for a total 1,100 days. Results: HC malfunction occurred in 23 cases (31.51%) during the study period, giving an overall rate of 21 episodes per 1,000 catheter days at risk. An analysis revealed a higher risk of HC malfunction with the catheterization of the femoral vein compared to the internal jugular vein (hazard ratio (HR) 6.3; 95% confidence interval (CI) 5.3–7.3). After correction for confounding factors in multivariate Cox analysis, the site of the catheterization remained a statistically significant predictor of HC malfunction (HR 5.03, 95% CI 3.83–6.23). After the first week malfunction rate was 42 and 8% for femoral and internal jugular site, respectively (relative risk (RR) for malfunction 5.3 (95% CI, 2.5–8). After the second and third week, the incidence of malfunction was 51 and 14% for femoral and internal jugular vein, respectively (RR 3.6, 95% CI 2.2–5.1). Conclusions: Catheterization of the internal jugular vein is associated with longer catheter survival when compared to the femoral vein. Hemodialysis catheters should be placed, if possible, in internal jugular vein to prevent their premature malfunction. Copyright © 2004 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
29. Lipid management in patients with chronic kidney disease.
- Author
-
Ferro, Charles J., Mark, Patrick B., Kanbay, Mehmet, Sarafidis, Pantelis, Heine, Gunnar H., Rossignol, Patrick, Massy, Ziad A., Mallamaci, Francesca, Valdivielso, Jose M., Malyszko, Jolanta, Verhaar, Marianne C., Ekart, Robert, Vanholder, Raymond, London, Gerard, Ortiz, Alberto, and Zoccali, Carmine
- Subjects
- *
CHRONIC kidney failure , *CARDIOVASCULAR diseases risk factors , *LIPID analysis , *HEMODIALYSIS , *ANTILIPEMIC agents , *CHOLESTEROL - Abstract
An increased risk of cardiovascular disease, independent of conventional risk factors, is present even at minor levels of renal impairment and is highest in patients with end-stage renal disease (ESRD) requiring dialysis. Renal dysfunction changes the level, composition and quality of blood lipids in favour of a more atherogenic profile. Patients with advanced chronic kidney disease (CKD) or ESRD have a characteristic lipid pattern of hypertriglyceridaemia and low HDL cholesterol levels but normal LDL cholesterol levels. In the general population, a clear relationship exists between LDL cholesterol and major atherosclerotic events. However, in patients with ESRD, LDL cholesterol shows a negative association with these outcomes at below average LDL cholesterol levels and a flat or weakly positive association with mortality at higher LDL cholesterol levels. Overall, the available data suggest that lowering of LDL cholesterol is beneficial for prevention of major atherosclerotic events in patients with CKD and in kidney transplant recipients but is not beneficial in patients requiring dialysis. The 2013 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Lipid Management in CKD provides simple recommendations for the management of dyslipidaemia in patients with CKD and ESRD. However, emerging data and novel lipid-lowering therapies warrant some reappraisal of these recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.